Transcranial Ultrasound in Clinical SONothrombolysis (TUCSON)

ImaRx Therapeutics

Status and phase: Terminated; Phase 2; Phase 1

Conditions: Acute Ischemic Stroke

Treatments: Drug: Placebo; Drug: MRX-801

Study type: Interventional

Funder types: Industry

Identifiers

NCT00504842

MRX-06-101-CP-01-01

Details and patient eligibility

About

This is a randomized, placebo controlled, parallel group dose escalation trial to evaluate the safety, tolerability, and activity of four sequential dose tiers of MRX-801 and ultrasound as an adjunctive therapy to tissue plasminogen activator (tPA) treatment in subjects with acute ischemic stroke.

Enrollment: 72 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Acute ischemic stroke
• Occlusion demonstrated by transcranial Doppler ultrasound
• Eligible for tPA

Exclusion criteria

• Right to left cardiac shunt
• Moderate to severe COPD
• Uncontrolled hypertension

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind